Archana Sharma, MD
Rheumatology · Bristol, CTNPI 1851524557
Payments from drug & device makers
Across 601 payments — averaging $162.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$90K
- Amgen$2K
- Lilly USA, LLC$596
- Mallinckrodt Hospital Products Inc.$498
- Johnson & Johnson$471
- GSK$437
- plus $4K from 36 others
What the payments were for
- Consulting fees$1000%
- Speaking & faculty fees$66,45068%
- Travel & lodging$18,88219%
- Food & beverage$11,88912%
- Education$2900%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 220 | $90,423 |
| Amgen(2 entities) | 95 | $1,564 |
| Lilly USA, LLC | 35 | $596 |
| Mallinckrodt Hospital Products Inc. | 22 | $498 |
| Johnson & Johnson | 28 | $471 |
| GSK | 23 | $437 |
| Novartis | 23 | $404 |
| UCB, Inc. | 18 | $368 |
| Pfizer | 25 | $331 |
| Genentech USA, Inc. | 16 | $330 |
| AstraZeneca | 14 | $275 |
| Sanofi | 9 | $210 |
| E.r. Squibb & Sons, L.L.C. | 7 | $172 |
| Radius Health, Inc. | 6 | $139 |
| ANI Pharmaceuticals, Inc. | 4 | $108 |
| Actelion Pharmaceuticals US, Inc. | 4 | $103 |
| Aurinia Pharma U.S., Inc. | 5 | $102 |
| Cardinal Health 110 LLC | 1 | $100 |
| Antares Pharma, Inc. | 4 | $91 |
| Boehringer Ingelheim | 4 | $90 |
| Fresenius Kabi USA, LLC | 4 | $89 |
| Abbott | 3 | $72 |
| Mallinckrodt Enterprises LLC | 5 | $71 |
| Bioventus LLC | 3 | $69 |
| Sobi, Inc | 2 | $57 |
| Pacira Therapeutics, Inc. | 3 | $57 |
| Neurocrine Biosciences, Inc. | 1 | $35 |
| Regeneron Healthcare Solutions, Inc. | 1 | $35 |
| Sandoz | 2 | $32 |
| Bristol Myers Squibb | 2 | $31 |
| Madrigal Pharmaceuticals | 1 | $30 |
| Almatica Pharma LLC | 1 | $27 |
| Kyowa Kirin, Inc. | 1 | $27 |
| Alvogen Inc | 1 | $24 |
| Insulet Corporation | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Medtronic | 1 | $23 |
| Corcept Therapeutics | 1 | $21 |
| Kerecis Limited | 1 | $19 |
| Amneal Pharmaceuticals LLC | 1 | $18 |
| Medexus Pharma, Inc. | 1 | $13 |
| Cequr Corporation | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$97,611 in reported general payments places this provider in the 85th percentile of 118 rheumatology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RinvoqUpadacitinib | 107 | $710,997 |
| Humira(Cf) PenAdalimumab | 86 | $675,853 |
| Orencia ClickjectAbatacept | 70 | $411,424 |
| Enbrel SureclickEtanercept | 45 | $326,175 |
| Xeljanz XrTofacitinib Citrate | 23 | $187,485 |
| Enbrel MiniEtanercept | 15 | $110,705 |
| OtezlaApremilast | 14 | $72,126 |
| Actemra ActpenTocilizumab | 19 | $66,895 |
| OrenciaAbatacept | 12 | $60,857 |
| Hydroxychloroquine Sulfate | 519 | $15,322 |
| RasuvoMethotrexate/Pf | 13 | $8,661 |
| MethotrexateMethotrexate Sodium | 401 | $6,164 |
| Leflunomide | 106 | $5,467 |
| Lidocaine | 22 | $4,937 |
| Gabapentin | 180 | $4,354 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $90,423 | $710,997107 claims |
| AmgenOtezla | $1,564 | $72,12614 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $172 | $60,85712 claims |
| Medexus Pharma, Inc.Rasuvo | $13 | $8,66113 claims |
| Amneal Pharmaceuticals LLCMycophenolate Mofetil | $18 | $1,86531 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 118 rheumatology providers in Connecticut.
Other rheumatology in Bristol
- Christon GrantBristol$5K
- Fotios KoumpourasNorth Haven$1.5M
- Kenneth MillerDanbury$930K
- Monique HinchcliffNorth Haven$883K
- Robert SchoenGuilford$638K
- Stuart NovackNorwalk$507K
- Bret SohnStamford$460K
- Geoffrey GladsteinTrumbull$452K
- John MagaldiTorrington$451K
- Joseph CraftNew Haven$357K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.